BRANDON BioCatalyst, a collaboration of more than 50 of Australia and New Zealand's leading medical research institutes, hospitals and universities, has announced new board appointments to continue the scaling of Australian medical research into globally competitive biotech companies.
Long-standing director and former Queensland Premier Peter Beattie is the new Chair.
A long-time champion of innovation, biotech and medical research, Beattie developed and championed the Queensland Smart State strategy that set up the Medical Research Institutes, which delivered Gardasil and, more recently, Vicebio.
"With Peter Beattie now at the helm, Brandon BioCatalyst remains focused on building a globally competitive life sciences ecosystem - one that attracts patient capital, delivers returns for investors, creates opportunities for skilled talent, and drives meaningful improvements in people's health," said Dr Chris Nave, Brandon BioCatalyst CEO.
Other appointments include Dr Andrew Nash, former Chief Scientific Officer at CSL, and Ross King, Managing Director and Founder of Treadstone Resources and former MD at Goldman Sachs Australia.
The above article was sent to subscribers in Pharmacy Daily's issue from 21 Aug 25
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 21 Aug 25
